Related Experiment Video
Updated: Jun 30, 2026
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Deucravacitinib in dermatology: current indication and existing off-label data
Michela D'Agostino1, Luca Potestio1, Nello Tommasino1
1Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Drugs in Context
|June 29, 2026
Summary
Tyrosine kinase 2 (TYK2) inhibition with deucravacitinib shows efficacy in psoriasis and psoriatic arthritis. Real-world data confirm benefits in diverse patients and potential for other inflammatory skin diseases.
Area of Science:
- Dermatology and immunology
- Pharmacology of targeted therapies
- Cytokine pathway modulation
Background:
- Tyrosine kinase 2 (TYK2) inhibition is a novel therapeutic strategy for immune-mediated inflammatory diseases.
- Deucravacitinib selectively inhibits TYK2, modulating IL-12, IL-23, and type I interferon signaling.
- This targeted approach offers potential safety advantages over broad-spectrum JAK inhibitors.
Purpose of the Study:
- To review current clinical evidence on deucravacitinib in dermatology.
- To focus on real-world data and emerging off-label applications of TYK2 inhibition.
- To assess the potential of deucravacitinib in various dermatological conditions beyond psoriasis.
Main Methods:
- Narrative review of clinical evidence.
- Analysis of pivotal randomized clinical trials.
- Examination of real-world studies, case series, and observational reports.
Main Results:
- Deucravacitinib demonstrates robust efficacy and sustained responses in moderate-to-severe plaque psoriasis and psoriatic arthritis.
- Real-world data confirm rapid improvement, durable responses, and favorable tolerability in psoriasis patients.
- Emerging evidence suggests potential benefits in cutaneous lupus erythematosus, dermatomyositis, alopecia areata, and other inflammatory dermatoses.
Conclusions:
- Deucravacitinib is an effective systemic therapy for psoriasis and psoriatic arthritis.
- Real-world data support its use in heterogeneous patient populations and difficult-to-treat areas.
- TYK2 inhibition shows promise for a broader range of dermatological conditions, warranting further investigation.
Related Concept Videos
01:27Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:19Clinical Applications of Epidermal Stem Cells
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
01:23Skin Diseases and Disorders
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...